These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 30448050)
1. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. Girmenia C; Candoni A; Delia M; Latagliata R; Molteni A; Oliva EN; Palumbo GA; Poloni A; Salutari P; Santini V; Voso MT; Musto P Blood Rev; 2019 Mar; 34():16-25. PubMed ID: 30448050 [TBL] [Abstract][Full Text] [Related]
2. Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. Girmenia C; Cavo M; Offidani M; Scaglione F; Corso A; Di Raimondo F; Musto P; Petrucci MT; Barosi G Blood Rev; 2019 Mar; 34():84-94. PubMed ID: 30683446 [TBL] [Abstract][Full Text] [Related]
3. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S; Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903 [TBL] [Abstract][Full Text] [Related]
4. The risk of infections in patients with myelodysplastic syndromes in 2016. Caira M; Latagliata R; Girmenia C Expert Rev Hematol; 2016 Jun; 9(6):607-14. PubMed ID: 27100058 [TBL] [Abstract][Full Text] [Related]
5. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine. Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924 [TBL] [Abstract][Full Text] [Related]
7. Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop. Platzbecker U; Santini V; Mufti GJ; Haferlach C; Maciejewski JP; Park S; Solé F; van de Loosdrecht AA; Haase D Leuk Res; 2012 Mar; 36(3):264-70. PubMed ID: 22137318 [TBL] [Abstract][Full Text] [Related]
8. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Stahl M; Zeidan AM Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851 [TBL] [Abstract][Full Text] [Related]
9. Current and Future Treatment Options for Myelodysplastic Syndromes: More Than Hypomethylating Agents and Lenalidomide? Sockel K; Platzbecker U Drugs; 2018 Dec; 78(18):1873-1885. PubMed ID: 30467725 [TBL] [Abstract][Full Text] [Related]
10. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Wells RA; Leber B; Buckstein R; Lipton JH; Hasegawa W; Grewal K; Yee K; Olney HJ; Larratt L; Vickars L; Tinmouth A Leuk Res; 2008 Sep; 32(9):1338-53. PubMed ID: 18405971 [TBL] [Abstract][Full Text] [Related]
11. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy. Wong CAC; Wong SAY; Leitch HA Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023 [TBL] [Abstract][Full Text] [Related]
12. Consensus statement on iron overload in myelodysplastic syndromes. Bennett JM; Am J Hematol; 2008 Nov; 83(11):858-61. PubMed ID: 18767130 [TBL] [Abstract][Full Text] [Related]
13. Update on the pharmacotherapy for myelodysplastic syndromes. Duong VH; Komrokji RS; List AF Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144 [TBL] [Abstract][Full Text] [Related]
14. [Current management of myelodysplastic syndromes]. Caers J; Bonnet C; Graux C; De Prijck B; Beguin Y Rev Med Suisse; 2011 Aug; 7(306):1634, 1636-8, 1640-3. PubMed ID: 21972730 [TBL] [Abstract][Full Text] [Related]
15. Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform. Valent P; Stauder R; Theurl I; Geissler K; Sliwa T; Sperr WR; Bettelheim P; Sill H; Pfeilstöcker M Expert Rev Hematol; 2018 Feb; 11(2):109-116. PubMed ID: 29292655 [TBL] [Abstract][Full Text] [Related]
16. [Management of myelodysplastic syndromes]. Duchmann M; Fenaux P; Cluzeau T Bull Cancer; 2015 Nov; 102(11):946-57. PubMed ID: 26410692 [TBL] [Abstract][Full Text] [Related]
17. Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa. Louw VJ; Bassa F; Chan SW; Dreosti L; Du Toit M; Ferreira M; Gartrell K; Gunther K; Jogessar V; Littleton N; Mahlangu J; McDonald A; Patel M; Pool R; Ruff P; Schmidt A; Sissolak G; Swart A; Verburgh E; Webb MJ S Afr Med J; 2011 Nov; 101(12):900-6. PubMed ID: 22273034 [TBL] [Abstract][Full Text] [Related]
18. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. Malcovati L Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858 [TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes and the role of iron overload. Harvey RD Am J Health Syst Pharm; 2010 Apr; 67(7 Suppl 2):S3-9. PubMed ID: 20332503 [TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Malcovati L; Hellström-Lindberg E; Bowen D; Adès L; Cermak J; Del Cañizo C; Della Porta MG; Fenaux P; Gattermann N; Germing U; Jansen JH; Mittelman M; Mufti G; Platzbecker U; Sanz GF; Selleslag D; Skov-Holm M; Stauder R; Symeonidis A; van de Loosdrecht AA; de Witte T; Cazzola M; Blood; 2013 Oct; 122(17):2943-64. PubMed ID: 23980065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]